Clarivate PLC (CLVT.N): Balance Sheet Wins as Life Sciences Exits at a Discount; Remain Neutral

Research evidence excerpt

Clarivate PLC (CLVT.N): Balance Sheet Wins as Life Sciences Exits at a Discount; Remain Neutral

Flash |

06 Jul 2026 23:23:44 ET │ 11 pages

Clarivate PLC (CLVT.N)

Balance Sheet Wins as Life Sciences Exits at a Discount; Remain Neutral

CITI'S TAKE

Neutral / High Risk We view CLVT's $600m sale of Life Sciences & Health (~40% below what

CLVT paid for DRG alone in 2020) as strategically reasonable (10x Adj. Price (06 Jul 26 16:00) US$2.44

EBITDA less Capex/implied ~5x Adj EBITDA) but initially see it as a Target price US$2.80

financially neutral transaction. The improved profile (higher margins, Expected share price return 14.8%

better revenue quality, reduced capital intensity, lower debt) should drive Expected dividend yield 0.0%

better EBITDA-to-FCF conversion, typically a positive multiple driver, but Expected total return 14.8%

these gains are offset by reduced growth expectations. The company is

Market Cap US$1,560M divesting ~$370M revenue (15-18% of total) that had "higher than

midpoint" ACV growth expectations, creating a near-term growth drag.

Management now guides to the "lower half of range" for organic

growth. Additionally, management's openness to "additional segment Peter Christiansen, CFAAC

divestitures" raises questions about ongoing portfolio strategy and +1-212-816-8702

suggests potential for further downsizing rather than growth focus. The peter.christiansen@citi.com

transaction doesn't change our fundamental view: CLVT remains fairly

Nicolette Radomski

valued with decent market positions but limited growth catalysts.

+1-716-730-7538

nicolette.radomski@citi.com

Notes from the Sellside Q&A Session: Key clarifications included:

Aditi Balachandran

+1-212-816-0903 1. Revenue composition details—while Life Sciences was majority

aditi.balachandran@citi.com